Ascend Laboratories, LLC Atorvastatin Calcium Tablets USP, 80 mg recall: Failed Dissolution Specifications
Failed Dissolution Specifications
The hazard: Potency, impurity or stability failure
An out-of-specification result prompted this notice — potency, an impurity, or stability over the shelf life.
What the notice says: Failed Dissolution Specifications
Why it matters: The product failed a specification test: it may contain more or less active ingredient than the label states, carry an impurity, or degrade before its expiry date. A sub-potent dose can leave a condition untreated; a super-potent one can cause an overdose.
Symptoms and when to call a doctor
The risk depends entirely on the drug. For a medicine where dose matters closely — a blood thinner, an anti-epileptic, a thyroid or heart medicine, insulin — talk to your prescriber before changing anything. Seek urgent care if you have symptoms that suggest too much drug, or if the condition the medicine controls starts breaking through.
This page is general information, not medical advice. If you feel unwell, a clinician who can see you is the only person able to judge your case.
Recall details
- Recall number
- D-0020-2026
- Published
- October 22, 2025
- Risk level
- Class II
- Status
- Ongoing
- Issued by
- U.S. Food and Drug Administration
- Brand
- Ascend Laboratories, LLC
- Product type
- Prescription & OTC drugs
- Distribution
- Nationwide
- Made in
- United States
- Lot / code info
- Lot#: 25140249, Exp. Dec. 2026 Lot#: 25140247, Exp. Dec. 2026 Lot#: 24144999, Exp. Nov. 2026 Lot#: 24144942, Exp. Nov. 2026 Lot#: 24144845, Exp. Nov. 2026 Lot#: 24144713, Exp. Nov. 2026 Lot#: 24144652, Exp. Oct. 2026 Lot#: 24143898, Exp. Aug. 2026 Lot#: 24143412, Exp. Aug. 2026 Lot#: 24143582, Exp. Aug. 2026
Products covered by this recall
Atorvastatin Calcium Tablets USP, 80 mg, Rx Only, a). 90-count(NDC 67877-514-90), b). 500-count(NDC 67877-514-05), Manufactured by: Alkem Laboratories, Ltd. India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054
Check your product
The notice names 19 codes you can read straight off the package. Type the one printed on yours and the list below narrows to it.
Lot or batch code
Usually ink-stamped near the seam, the cap or the bottom of the pack.
- 25140249
- Exp. Dec. 2026 Lot
- 24144999
- Exp. Nov. 2026 Lot
- 24144845
- 24144652
- Exp. Oct. 2026 Lot
- 24143412
- Exp. Aug. 2026 Lot
Best-by / use-by date
Printed beside the lot code, not on the price sticker.
- Dec. 2026 Lot
- Nov. 2026 Lot
- Oct. 2026 Lot
- Aug. 2026 Lot
- Aug. 2026
NDC number
On the carton and again on the bottle or blister label.
- 67877-514-90
- 67877-514-05
Package size
Match the net weight or the piece count on the front of the pack.
- 80 mg
- 90 count
- 500 count
Codes are lifted verbatim from the FDA — Drug enforcement notice. A code that is missing here may still be covered — the official notice is the complete list.
What to do about Potency
Ascend Laboratories, LLC — An out-of-specification result prompted this notice — potency, an impurity, or stability over the shelf life.
- Check the lot number on your pack against the codes listed above before you do anything else.
- Do not stop a prescription on your own. For most conditions an uncertain dose is safer than no dose while you get advice.
- Call your prescriber or pharmacist and ask whether to swap the lot, re-test, or change nothing.
- Keep the carton and the leaflet — the lot number is usually printed only on the outer pack.
What the company owes you
A recalled medicine is the manufacturer’s cost to carry, not yours or your pharmacist’s.
- The purchase price or co-pay is refundable, and so is the cost of returning the product if they ask you to ship it.
- Ask the pharmacy to handle the claim where they can — they process recall returns in bulk and it saves you the correspondence.
- Keep the carton, the leaflet and the pharmacy label together until the claim is closed.
- Costs beyond the price of the medicine need to go to the company directly, in writing, with the recall number quoted.
Company contact: Ascend Laboratories, LLC — 135 Us Highway 202 206 Ste 15, Bedminster, NJ, 07921-2608
The official notice
This page summarises a notice published by U.S. Food and Drug Administration. The agency notice is the authoritative version — read it before you act, and treat it as the final word if anything here looks different.
Open the FDA — Drug enforcement record U.S. Food and Drug Administration recalls
Questions people ask about this recall
Why was Ascend Laboratories, LLC prescription & otc drugs recalled?
Failed Dissolution Specifications Failed Dissolution Specifications
How do I know if I have the recalled product?
Match the codes printed on your package against the notice: lot code 25140249, Exp. Dec. 2026 Lot, 24144999; best-by date Dec. 2026 Lot or Nov. 2026 Lot. If the code on your package is not on that list, your unit is outside the recall.
What should I do with it right now?
Check the lot number on your pack against the codes listed above before you do anything else.
Can I get my money back?
The purchase price or co-pay is refundable, and so is the cost of returning the product if they ask you to ship it.
Where was the recalled product sold?
It was distributed nationwide.
Related recalls
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran Etexilate Capsules, 75 mg recall: Failed impurity/degradation specification: an OOS result observed in Related
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran Etexilate Capsules, 75 mg recall: Failed impurity/degradation specification: an OOS result observed in Related
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran Etexilate Capsules, 150 mg recall: Failed impurity/degradation specification: an OOS result observed in Related
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran etexilate Capsules, 150 mg, 20-count carton recall: Failed Impurities/Degradation Specifications: OOS result was observed during
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II…
-
Class II · 3 months ago
Ascend Laboratories, LLC Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg recall: Failed Dissolution Specifications; Olmesartan Medoxomil content below
Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran etexilate Capsules, 110 mg, 60-count carton recall: Failed Impurities/Degradation Specifications: OOS result was observed during
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II…